


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
UTHR
United Therapeutics Corpo
$476.59
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market
Chart
$422.53 (+12.79%)
$305.38 (+56.06%)
$284.27 (+67.65%)
$370.12 (+28.77%)
UTHR has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

UTHR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
UTHR Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
UTHR Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is UTHR current stock price?
What are UTHR stock strengths?
What is UTHR Risk Level?
What is UTHR market cap and volume?
What is UTHR current Stock IQ?
Should I buy UTHR stock right now?
Is UTHR a Strong Buy right now?
What does a 'Strong Buy' rating mean for UTHR?
What does a 'Strong Sell' rating mean for UTHR?
What factors influence UTHR's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
UTHR
United Therapeutics Corpo
Current Price
$476.59
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Chart
$422.53 (+12.79%)
$305.38 (+56.06%)
$284.27 (+67.65%)
$370.12 (+28.77%)
UTHR Analysts Opinion
UTHR Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
UTHR Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
UTHR Street Sentiment is extremely bullish and have positive views on the near-term outlook
UTHR has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels.
UTHR Latest Analysis
United Therapeutics Corporation (UTHR) Presents at Jefferies London Healthcare Conference 2025 Transcript.
Today
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wed Nov 12, 2025
United Therapeutics Corporation (UTHR) Presents at UBS Global Healthcare Conference 2025 Transcript.
Mon Nov 10, 2025
UBS Maintains United Therapeutics (UTHR) Buy Recommendation. Fintel reports that on November 6 2025 UBS maintained coverage of United Therapeutics (NasdaqGS:UTHR) with a Buy recommendation. Analyst Price Forecast Suggests 10.10% Upside
Fri Nov 7, 2025
Heres Why United Therapeutics (UTHR) is a Strong Value Stock. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wed Nov 5, 2025
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term. Wondering how to pick strong market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tue Nov 4, 2025
Wells Fargo Maintains United Therapeutics (UTHR) Equal-Weight Recommendation. Fintel reports that on October 30 2025 Wells Fargo maintained coverage of United Therapeutics (NasdaqGS:UTHR) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 9.73% Upside
Thu Oct 30, 2025
United Therapeutics Rockets 15% On Growing Enthusiasm For Its Top Drug. Shares of United Therapeutics rocketed early Wednesday despite mixed sales of its bread-and-butter drug Tyvaso.The post United Therapeutics Rockets 15% On Growing Enthusiasm For Its Top Drug appeared first on Investor'.s Business Daily.
Wed Oct 29, 2025
Compared to Estimates United Therapeutics (UTHR) Q3 Earnings: A Look at Key Metrics. Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2025 it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Wed Oct 29, 2025
United Therapeutics (UTHR) Beats Q3 Earnings Estimates. United Therapeutics (UTHR) delivered earnings and revenue surprises of 3.92% and -2.24% respectively for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Wed Oct 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
UTHR Stock trends
UTHR Stock performance
UTHR Stock analysis
UTHR investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.